Cargando…
Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy
With the in-depth exploration on cancer therapeutic nanovaccines, increasing evidence shows that the poor delivery of nanovaccines to lymphoid organs has become the culprit limiting the rapid induction of anti-tumor immune response. Unlike the conventional prophylactic vaccines that mainly form a de...
Autores principales: | Cai, Ting, Liu, Huina, Zhang, Shun, Hu, Jing, Zhang, Lingxiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620195/ https://www.ncbi.nlm.nih.gov/pubmed/34823541 http://dx.doi.org/10.1186/s12951-021-01146-2 |
Ejemplares similares
-
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
por: Li, Yueyi, et al.
Publicado: (2023) -
Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy
por: He, Ao, et al.
Publicado: (2023) -
A Magnetic Nanovaccine Enhances Cancer Immunotherapy
por: Guo, Yugang, et al.
Publicado: (2019) -
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022) -
Pulmonary delivery of mucosal nanovaccines
por: Tang, Wei, et al.
Publicado: (2021)